Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Vobra-duo is discontinued at long last.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
While Sutro shows why it’s shelved luvelta-T.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
The company buys Belgium’s EsoBiotec for $425m.
